QUOTE AND NEWS
Business Wire  Feb 8  Comment 
AmerisourceBergen (NYSE:ABC) announced a unique offering designed to help hospitals and health systems achieve meaningful use readiness for electronic health records (EHR), regardless of the technology they are using. The offering will be provided
Stock Blog Hub  Feb 6  Comment 
AmerisourceBergen Corporation (ABC) recently declared a dividend of 8 cents per share. The company pays an industry-leading dividend yield of 1.13%. In late January, the company reported record earnings of 52 cents for the fiscal first quarter,...
Market Intelligence Center  Feb 5  Comment 
AmerisourceBergen (NYSE: ABC) closed yesterday at $27.42. So far the stock has hit a 52-week low of $13.75 and 52-week high of $28.61. The proprietary Key Risk Ranking for ABC has declined from a 5 KEY Lowest Relative Risk to a 4 KEY Low Relative...
Market Intelligence Center  Feb 1  Comment 
AmerisourceBergen (NYSE: ABC) closed yesterday at $27.26. So far the stock has hit a 52-week low of $13.75 and 52-week high of $28.00. AmerisourceBergen stock has been showing support around 26.99 and resistance in the 27.75 range. Technical...
Business Wire  Jan 27  Comment 
The Board of Directors of AmerisourceBergen Corporation (NYSE:ABC) today declared a cash dividend of $0.08 per share on Common Stock, payable March 1, 2010 to stockholders of record at the close of business on February 12, 2010. About
Market Intelligence Center  Jan 27  Comment 
AmerisourceBergen (NYSE: ABC) closed yesterday at $27.44. So far the stock has hit a 52-week low of $13.75 and 52-week high of $28.00. AmerisourceBergen stock has been showing support around 26.93 and resistance in the 28.25 range. Technical...
Stock Blog Hub  Jan 26  Comment 
This morning, AmerisourceBergen Corp. (ABC) posted first quarter fiscal 2010 earnings of 52 cents per share, beating the Zacks Consensus Estimate by 6 cents. Earnings increased 44% from the year-ago period. Performance was driven by strong...
MarketWatch  Jan 26  Comment 
Pharmaceutical group AmerisourceBergen on Tuesday reported fiscal first-quarter net income of $151.3 million against $111 million in the same period a year ago. The company earned 52 cents a diluted share, a 44% gain over 36 cents in the same...
StreetInsider.com  Jan 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/AmerisourceBergen+%28ABC%29+Posts+Q4+EPS+of+%240.52%2C+Beats+by+8c%3B+Guides+FY10+EPS/5273890.html for the full story.
Business Wire  Jan 26  Comment 
AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2010 first quarter, ended December 31, 2009, diluted earnings per share were $0.52, a 44 percent increase. Revenue in the quarter was a record $19.3 billion, up 11.5



Thank you for your suggestion
 
TOP CONTRIBUTORS

This article refers to the drug wholesaler. For the broadcaster ABC, see Walt Disney Company (DIS).

AmerisourceBergen (NYSE: ABC) sells drugs to health care providers such as hospitals, pharmacies and clinics. The company acts as an intermediary, or middleman, between drug manufacturers and providers and ranks as the third-largest U.S. pharmaceutical distributor in the $250B pharmaceutical distribution industry, behind McKesson (MCK) and Cardinal Health (CAH). Drug distributors provide the specialized delivery services to end consumers. They ensure that the drugs are stored and transported under the prescribed conditions (adequate refrigeration, pressure, etc.) and delivered to secure locations.

Whereas the company's competitors have expanded into medical product manufacturing, healthcare information technology, and other services,[1] [2] ABC remains focused on pharmaceutical distribution.

With over $69B in pharmaceuticals slated to lose patent protection from 2007-2011, lower cost generic drugs carry the very real potential to lower revenue and profits for distributors like ABC. Although ABC earns higher margins on generic drugs, the company earns significantly less in terms of absolute profit from generic drugs because of their lower prices.

Business Overview

Following the spin-off of their PharMerica Long-Term Care business, which provided pharmacy products and services to residents and patients in long-term healthcare facilities, ABC has three main business segments.[3]

  1. Pharmaceutical Distribution: ABC is an intermediary, or middleman, between drug manufacturers and providers (e.g. pharmacies). The company mainly warehouses and distributes branded and generic drugs to hospitals, pharmacies, clinics, and other customers. In 2007, this represented over $48B in operating revenue.[4]
  2. Specialty Distribution: representing over $12B in operating revenue in fiscal 2007, ABC's specialty pharmaceuticals business is the leader in oncology products and also a leading distributor of vaccines and other injectables. [5]
  3. PMSI: provides home delivery of prescription drugs (through mail order and on-line pharmacy services) to patients under workers’ compensation programs. In 2007, this represented over $400M in operating revenue.[6]
ABC 2007 Annual Report
ABC 2007 Annual Report[7]

Operating revenue of $61.7 billion in fiscal 2007, increased 9% from the prior fiscal year due to growth in all business segments. Operating income of $820M in fiscal 2007 increased 9.5% from 2006. This increase was primarily due to an increase in compensation under fee-for-service agreements and the growth of generic drug distribution. Margins in the distribution business are very thin (ranging from 1-3%) -- therefore volume is very important for generating income.

ABC 2007 Annual Report
ABC 2007 Annual Report[8]

Trends & Forces

Declining growth of pharmaceutical sales

Historically, the most significant trend that has affected the pharmaceutical distribution business has been the volume and price of drugs purchased in the United States. Distributors such as ABC benefit directly from a greater amount of pharmaceuticals consumed by the American public. Although total pharmaceutical market sales have been increasing for the past years, the growth has fallen from about 18% at the beginning of 2001 to 5% in 2005.

The decline in growth has been attributed to a shrinking number of “blockbuster drugs,” or popular, trendy pharmaceuticals, as patents expired and consumers purchased cheaper generic versions. Less expensive drugs result in lower total market sales, and less profit for distributors. Second, changes in health care such as tighter regulations and cost shifting to consumers have adversely affected total market sales.

Fee-for-Service Compensation leads to less volatile revenue

The entire pharmaceutical distribution industry has undergone significant changes in recent years, as the compensation system changed from forward buying to fee-for-service payment. Before the transition, wholesalers such as ABC would buy pharmaceuticals ahead of receiving any orders from pharmacies & hospitals, hold them, and hope that the demand and prices of these drugs would go up (primarily due to inflation) in the holding period. However, profit margins shrank as the growth in the price of branded pharmaceuticals slowed. Distributors are now reimbursed by fee-for-service payments, as customers negotiate contracts to pay a certain fee for deliveries and additional services. These changes result in a steadier, more controlled cash-flow for distributors.

Generic Drugs Drive margin growth, but may depress revenue

The growth of generic drugs represents both an opportunity and a threat for ABC. The drugs have margins up to 5 times higher than generic drugs of branded pharmaceuticals. Generic drugs are also much cheaper than their more exclusive counterparts. With $13.6 billion in branded drugs sales losing patent protection in 2006 and a projected $69 billion in branded drug sales losing protection from 2007-2011, generic drugs can also have the potential to dramatically lower overall revenue growth in the in the pharmaceutical industry.

  • Benefits

Because generics are much like normal commodities, they have a large reliance on wholesalers. Because wholesalers contract packages with multiple pharmaceuticals to their clients, they can essentially guarantee their clients as buyers for a generic drug. Therefore, wholesalers control a significant portion of the demand for any individual generic. Competition amongst generic manufacturers allows wholesalers to then extract better terms from the manufacturers, hence the much higher profit margins with generics than with branded drugs. Furthermore, generic distribution involves lower inventory and general operating costs.

  • Pitfalls

There is no guarantee that the pharmaceutical distribution business can maintain profits as the market shifts towards generic drugs. Although currently the generic drugs have a positive impact on the distribution industry, there are concerns that competition between generics could hurt profits. When competition causes prices to collapse, absolute earnings begin to fall, and sometimes distributors earn less with generics than they did previously with the branded version. This occurs when a generic drug’s price is about 3% of its branded version’s price.

Wal-Mart Threatens Drug Distribution Model

In 2006, Wal-Mart announced it would sell nearly 300 drugs for $4 in its Tampa Bay stores. Wal-Mart buys most of its generics directly from manufactures, leaving out distributors such as ABC. Since then, Wal-Mart has expanded its $4 generic drug distribution to 16 states and nearly 360 drugs. [9] Given that Wal-Mart has over 4,000 stores in the US and a presence in nearly every major metropolitan market, it could have a major impact on the pricing and margins of generic drugs. This could lead other retail pharmacies to try to purchase generics directly from manufacturers, which would hurt ABC's generic distribution business.

Market Share

ABC competes in the pharmaceutical distribution market primarily with McKesson (MCK) and Cardinal Health (CAH). ABC has around 23% market share, trailing MCK and CAH. Combined, the triumvirate account for over 80% of sales in the distribution industry.

image: Pharmadist.JPG

Competition

Below is a graph comparing the percentages of revenue from the different segments of the three major players. Notice that ABC is much less diversified than the other two.

Company Distribution Med/Surg Supplies Provider IT Automation Services Long-term care pharmacy Revenues ($B)
AmerisourceBergen 99% n/a n/a n/a n/a $61.7
Cardinal Health (CAH)[10] 80% 13% 4% 3% n/a $81.4
McKesson (MCK)[11] 94% 4% 2% n/a n/a $93.0





References

  1. MCK 10K 2007
  2. CAH 10K 2006
  3. ABC 10K 2007, Pg 4
  4. ABC 10K 2007, Pg 2
  5. ABC 10K 2007, Pg 3
  6. ABC 10K 2007, Pg 4
  7. ABC 10K 2007
  8. ABC 10K 2007
  9. Wal-Mart Pharmacy
  10. CAH 10K 2006
  11. MCK 10K 2007
Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki